

Special Issue

New Advances on Zika Virus Research

Message from the Guest Editors

Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family that has been known to cause sporadic outbreaks in Africa and Southeast Asia. Recently, ZIKV has been associated with Guillain-Barre syndrome and microcephaly in the infants of infected mothers, a condition where infants are born with abnormally-small heads. To date, there are no Food and Drug Administration (FDA)-licensed prophylactics (vaccines) or therapeutics (antivirals) available for the treatment of ZIKV disease in humans, which has the potential to affect millions of people worldwide. The significance of ZIKV in human health, together with the limited existing armamentarium to combat ZIKV infection, highlight the importance of developing effective countermeasures to prevent or treat ZIKV infection in humans. In this Special Issue, we will focus on the most recent discoveries in ZIKV research, including the molecular biology of the virus, virus–host interactions, antivirals, and vaccine development.

Guest Editors

Prof. Dr. Luis Martinez-Sobrido

Disease Prevention and Intervention Program, Texas Biomedical Research Institute, San Antonio, TX, USA

Dr. Fernando Almazan Toral

Department of Molecular and Cell Biology, National Center for Biotechnology, Darwin 3, 28049 Madrid, Spain

Deadline for manuscript submissions

closed (30 September 2018)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/13321

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).